NASDAQ:ATRC - AtriCure Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $88.67
  • Forecasted Upside: 112.27 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$41.77
▼ -1.31 (-3.04%)

This chart shows the closing price for ATRC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AtriCure Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATRC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATRC

Analyst Price Target is $88.67
▲ +112.27% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for AtriCure in the last 3 months. The average price target is $88.67, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 112.27% upside from the last price of $41.77.

This chart shows the closing price for ATRC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in AtriCure. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/24/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/21/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/19/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/17/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/18/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/4/2022Needham & Company LLCLower Price Target$79.00 ➝ $67.00High
3/14/2022BTIG ResearchReiterated RatingBuy$94.00Medium
2/24/2022Needham & Company LLCReiterated RatingBuy$79.00High
2/16/2022Canaccord Genuity GroupLower Price Target$120.00 ➝ $88.00High
2/16/2022Needham & Company LLCLower Price TargetBuy$92.00 ➝ $79.00High
2/16/2022Canaccord Genuity GroupLower Price TargetBuy$120.00 ➝ $88.00High
11/4/2021SVB LeerinkBoost Price TargetOutperform$100.00 ➝ $110.00High
11/4/2021Needham & Company LLCBoost Price TargetBuy$90.00 ➝ $92.00High
8/5/2021Needham & Company LLCLower Price TargetBuy$91.00 ➝ $90.00High
8/5/2021SVB LeerinkBoost Price TargetOutperform$95.00 ➝ $100.00High
8/5/2021OppenheimerDowngradeOutperform ➝ Market PerformHigh
6/15/2021Stifel NicolausBoost Price TargetPositive ➝ Buy$72.00 ➝ $85.00High
5/26/2021SVB LeerinkBoost Price TargetOutperform$78.00 ➝ $95.00High
5/17/2021Needham & Company LLCReiterated RatingBuy$91.00High
5/14/2021JPMorgan Chase & Co.Boost Price TargetOverweight$70.00 ➝ $81.00Low
4/29/2021Piper SandlerBoost Price Target$70.00 ➝ $85.00Medium
4/29/2021SVB LeerinkReiterated RatingBuyHigh
4/28/2021Needham & Company LLCBoost Price TargetBuy$74.00 ➝ $81.00High
4/28/2021OppenheimerBoost Price TargetOutperform$65.00 ➝ $75.00High
4/28/2021BTIG ResearchBoost Price TargetBuy$69.00 ➝ $76.00High
2/24/2021SVB LeerinkBoost Price TargetOutperform$65.00 ➝ $78.00Low
2/24/2021Needham & Company LLCBoost Price TargetBuy$63.00 ➝ $74.00High
1/29/2021Piper SandlerBoost Price TargetOverweight$50.00 ➝ $66.00Medium
1/21/2021BTIG ResearchBoost Price TargetIn-Line ➝ Buy$56.00 ➝ $66.00Low
12/18/2020Needham & Company LLCBoost Price TargetBuy$53.00 ➝ $63.00High
12/14/2020SVB LeerinkBoost Price TargetOutperform$60.00 ➝ $65.00High
11/6/2020Needham & Company LLCLower Price TargetBuy$63.00 ➝ $53.00Medium
7/29/2020JPMorgan Chase & Co.Boost Price TargetOverweight$48.00 ➝ $57.00High
7/29/2020SVB LeerinkBoost Price TargetOutperform$55.00 ➝ $60.00High
7/29/2020Piper SandlerBoost Price TargetPositive ➝ Overweight$47.00 ➝ $50.00High
7/28/2020BTIG ResearchReiterated RatingBuy$56.00High
5/11/2020BTIG ResearchBoost Price TargetBuy$45.00 ➝ $56.00High
5/11/2020SVB LeerinkBoost Price TargetOutperform$50.00 ➝ $55.00High
5/11/2020OppenheimerBoost Price TargetOutperform$45.00 ➝ $52.00High
5/8/2020Needham & Company LLCReiterated RatingBuy$49.00Medium
4/29/2020BTIG ResearchReiterated RatingBuy$45.00High
4/28/2020JPMorgan Chase & Co.Lower Price TargetOverweight$47.00 ➝ $39.00Medium
4/19/2020OppenheimerInitiated CoverageOutperform$45.00Low
4/6/2020OppenheimerInitiated CoverageOutperform$45.00High
2/19/2020Piper SandlerBoost Price Target$40.00 ➝ $50.00Medium
2/19/2020Needham & Company LLCBoost Price TargetBuy$48.00 ➝ $52.00High
2/19/2020BTIG ResearchBoost Price TargetBuy$42.00 ➝ $48.00High
2/6/2020BTIG ResearchInitiated CoverageBuy$42.00Medium
1/27/2020Piper SandlerReiterated RatingBuy$40.00High
1/24/2020Needham & Company LLCReiterated RatingBuy$39.00 ➝ $48.00Low
1/21/2020BTIG ResearchReiterated RatingBuy ➝ Outperform$42.00Low
9/6/2019JPMorgan Chase & Co.Reiterated RatingBuyMedium
8/13/2019BTIG ResearchReiterated RatingBuy$35.00High
8/13/2019Northland SecuritiesDowngradeOutperform ➝ Market Perform$30.00High
8/12/2019Piper Jaffray CompaniesSet Price TargetBuy$40.00Medium
8/12/2019Needham & Company LLCSet Price TargetBuy$39.00Medium
4/26/2019Northland SecuritiesReiterated RatingBuyHigh
4/12/2019JPMorgan Chase & Co.Initiated CoverageOverweight$37.00Medium
4/2/2019BTIG ResearchUpgradeNeutral ➝ Buy$35.00High
3/28/2019Needham & Company LLCReiterated RatingBuy$39.00High
3/5/2019BTIG ResearchReiterated RatingHoldLow
11/2/2018Needham & Company LLCReiterated RatingBuy$39.00High
10/12/2018Needham & Company LLCReiterated RatingBuy$39.00Medium
10/4/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$36.00 ➝ $39.00High
8/2/2018Stifel NicolausBoost Price TargetBuy$32.00 ➝ $34.00High
8/2/2018BTIG ResearchReiterated RatingHoldHigh
8/2/2018Needham & Company LLCReiterated RatingBuy$32.00 ➝ $36.00High
6/27/2018BTIG ResearchReiterated RatingHoldMedium
6/27/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$23.00 ➝ $32.00Medium
6/26/2018Piper Jaffray CompaniesBoost Price TargetOverweight$30.00Medium
6/18/2018Needham & Company LLCBoost Price TargetBuy$26.00 ➝ $32.00High
4/27/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$22.00 ➝ $23.00High
4/27/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$23.00 ➝ $26.00High
2/27/2018Needham & Company LLCReiterated RatingBuy$23.00High
1/16/2018Needham & Company LLCReiterated RatingBuy$25.00 ➝ $23.00Low
12/10/2017Piper Jaffray CompaniesReiterated RatingBuy$24.00Low
11/2/2017Needham & Company LLCLower Price TargetBuy ➝ Buy$26.00 ➝ $25.00N/A
7/30/2017Stifel NicolausReiterated RatingBuy$25.00Medium
7/28/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$25.00 ➝ $26.00High
6/16/2017SVB LeerinkReiterated RatingOutperform$26.00Low
5/30/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$26.00Low
(Data available from 5/19/2017 forward)

News Sentiment Rating

0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2021
  • 6 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/20/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/20/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/19/2022
  • 0 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 4 very negative mentions
2/18/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/20/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
4/19/2022
  • 2 very positive mentions
  • 18 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
5/19/2022

Current Sentiment

  • 2 very positive mentions
  • 18 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
AtriCure logo
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Read More

Today's Range

Now: $41.77
Low: $41.33
High: $42.75

50 Day Range

MA: $56.85
Low: $39.59
High: $66.36

52 Week Range

Now: $41.77
Low: $38.64
High: $89.18

Volume

309,226 shs

Average Volume

334,676 shs

Market Capitalization

$1.93 billion

P/E Ratio

37.29

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of AtriCure?

The following Wall Street research analysts have issued reports on AtriCure in the last year: BTIG Research, Canaccord Genuity Group Inc., Needham & Company LLC, Oppenheimer Holdings Inc., Stifel Nicolaus, StockNews.com, SVB Leerink LLC, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ATRC.

What is the current price target for AtriCure?

0 Wall Street analysts have set twelve-month price targets for AtriCure in the last year. Their average twelve-month price target is $88.67, suggesting a possible upside of 112.3%.
View the latest price targets for ATRC.

What is the current consensus analyst rating for AtriCure?

AtriCure currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATRC will outperform the market and that investors should add to their positions of AtriCure.
View the latest ratings for ATRC.

How do I contact AtriCure's investor relations team?

AtriCure's physical mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company's listed phone number is (513) 755-4100 and its investor relations email address is [email protected] The official website for AtriCure is www.atricure.com. Learn More about contacing AtriCure investor relations.